Welcome to our dedicated page for Novanta news (Ticker: NOVT), a resource for investors and traders seeking the latest updates and insights on Novanta stock.
Novanta Inc. (Nasdaq: NOVT) is a global supplier of core technology solutions for medical, life science, and advanced industrial original equipment manufacturers. As a trusted technology partner to medical and advanced technology equipment manufacturers, the company frequently features in news related to its financial performance, capital markets activity, and participation in investor and industry conferences.
News about Novanta often includes quarterly earnings releases and related conference call announcements, where the company reports GAAP results alongside non-GAAP metrics such as Adjusted EBITDA, Adjusted Diluted EPS, and Organic Revenue Growth. These updates provide insight into how its precision medicine, precision manufacturing, medical solutions, robotics and automation, and advanced surgery businesses are performing.
Investors can also expect coverage of capital structure developments, such as the offering and pricing of tangible equity units that combine prepaid stock purchase contracts with senior amortizing notes, as well as amendments to credit agreements and details of senior credit facilities. Announcements about share repurchase authorizations by the Board of Directors are another recurring news theme, reflecting decisions on capital allocation.
In addition, Novanta regularly appears in conference and investor event schedules, including healthcare and industrial conferences hosted by firms such as J.P. Morgan, Baird, Jefferies, and CJS Securities. These events highlight management’s engagement with the investment community and provide forums for discussing strategy and market positioning.
This news page aggregates such items in one place, helping readers follow Novanta’s earnings announcements, financing activities, share repurchase plans, and public presentations over time.
Summary not available.
Summary not available.
Summary not available.
Novanta Inc. (NASDAQ: NOVT) will release its Q1 2023 results on May 9, 2023. A conference call is scheduled for 10:00 a.m. ET on the same day to discuss the financial performance. Investors can participate by dialing (888) 346-3959 or through a live webcast available on the company’s website. A replay of the call will be accessible approximately three hours after its conclusion and will remain available until July 3, 2023. Novanta is recognized as a leading global supplier of technology solutions for healthcare and industrial OEMs, providing advanced components and systems designed for precision and superior performance.
Novanta reported a strong financial performance for the full year 2022, with GAAP revenue increasing by 22% to $861 million and net income rising to $74 million. The company achieved a 46% increase in diluted EPS, reaching $2.06. Adjusted EPS also grew by 17% to $3.07, while adjusted EBITDA was reported at $184 million. For Q4 2022, revenue rose 9.8% to $218.4 million. Looking ahead, Novanta projects 2023 GAAP revenue between $890 million and $915 million with adjusted diluted EPS expected between $3.00 and $3.20.
Novanta Inc. (NASDAQ: NOVT) will announce its fourth quarter and full year 2022 results on March 1, 2023. The company is a trusted partner for medical and advanced technology equipment manufacturers, offering core technology solutions to enhance performance. A conference call is scheduled for 10:00 a.m. ET on the same day to discuss results, accessible via phone or a live webcast through its website. A replay of the call will be available for three hours after the event until April 3, 2023. For more information, visit Novanta's website.
Novanta Inc. (NASDAQ: NOVT), a leader in technology solutions for medical and advanced technology equipment manufacturers, announced that Robert Buckley, CFO, and Chuck Ravetto, Group President, will present at the CJS Securities 23rd Annual New Ideas for the New Year Investor Conference on Wednesday, January 11, 2023. The conference will be held virtually, highlighting Novanta's commitment to innovation and customer success as they deliver precise technology solutions to OEMs.
Novanta Inc. (NASDAQ: NOVT) announced that its Chair & CEO, Matthijs Glastra, along with CFO Robert Buckley, will present at the J.P. Morgan Healthcare Conference in San Francisco, California, on January 10, 2023. As a global supplier of technology solutions for medical and advanced industrial OEMs, Novanta specializes in photonics, vision, and precision motion technologies. The company's expertise enables it to deliver high-performance components tailored to customer needs, driving growth through innovation and commitment to success.
Novanta reported a 26% increase in GAAP revenue to $223 million for Q3 2022, alongside a 66% rise in diluted EPS to $0.63. The company posted a net income of $22 million, up from $13.6 million year-over-year. Adjusted EBITDA was $49 million, reflecting robust performance despite inflationary pressures. Novanta raised its 2022 guidance, expecting GAAP revenue of $857-$859 million for the year, indicating 21-22% growth. Customer demand remains strong, with backlog levels near record highs.
Novanta Inc. (NASDAQ: NOVT), a technology partner for medical and advanced tech equipment manufacturers, announced that CEO Matthijs Glastra and CFO Robert Buckley will present at the Baird 2022 Global Industrial Conference in Chicago on November 9, 2022. The company specializes in providing core technology solutions that enhance OEMs' competitive advantage, focusing on photonics, vision, and precision motion technologies. Novanta’s commitment to innovation and customer success drives its growth in delivering precision-engineered components.
FAQ
What is the current stock price of Novanta (NOVT)?
What is the market cap of Novanta (NOVT)?
